MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529411 | Name: ADX-10061

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ADX-10061, also known as CEE-03-310 and NNC-01-0687, is a dopamine D1 receptor antagonist potentially for the treatment of smoking cessation, sleep disorder

Chemical Structure

ADX-10061
CAS#128022-68-4

Theoretical Analysis

MedKoo Cat#: 529411

Name: ADX-10061

CAS#: 128022-68-4

Chemical Formula: C19H20N2O4

Exact Mass: 340.1423

Molecular Weight: 340.38

Elemental Analysis: C, 67.05; H, 5.92; N, 8.23; O, 18.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ADX-10061; CEE-310; CEE-03-310; NNC-01-0687; NNC-687; ADX10061; CEE310; CEE03310; NNC010687; NNC687; ADX 10061; CEE 310; CEE 03 310; NNC 01 0687; NNC 687
IUPAC/Chemical Name
(S)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol
InChi Key
XZPSYCOYKJRHKE-MRXNPFEDSA-N
InChi Code
InChI=1S/C19H20N2O4/c1-20-7-5-13-9-17(21(23)24)18(22)10-15(13)16(11-20)14-4-2-3-12-6-8-25-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
SMILES Code
OC1=C([N+]([O-])=O)C=C2CCN(C)C[C@H](C3=C(OCC4)C4=CC=C3)C2=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 340.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Grodum E, Andersen M, Hangaard J, Koldkjaer O, Hagen C. Lack of effect of the dopamine D1 antagonist, NNC 01-0687, on unstimulated and stimulated release of anterior pituitary hormones in males. J Endocrinol Invest. 1998 May;21(5):291-7. PubMed PMID: 9648050. 2: Skrumsager BK, Christensen JV, Snel S, Seiberling M. Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. Psychopharmacology (Berl). 1995 Oct;121(3):294-9. PubMed PMID: 8584609. 3: Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C, Sloth-Nielsen M, Skrumsager BK, Lublin H, Gerlach J. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl). 1995 Oct;121(3):328-9. PubMed PMID: 8584614. 4: Christensen JV. Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5- tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography. J Chromatogr. 1992 Jun 10;577(2):366-70. PubMed PMID: 1301070. 5: Eder DN, Zdravkovic M, Wildschiødtz G. Selective alterations of the first NREM sleep cycle in humans by a dopamine D1 receptor antagonist (NNC-687). J Psychiatr Res. 2003 Jul-Aug;37(4):305-12. PubMed PMID: 12765853. 6: Eder DN. CEE-03-310 CeNeS pharmaceuticals. Curr Opin Investig Drugs. 2002 Feb;3(2):284-8. Review. PubMed PMID: 12020061. 7: Ahlenius S. Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol. 1999 May;84(5):193-6. Review. PubMed PMID: 10361974. 8: Salmi P, Ahlenius S. Dihydrexidine produces hypothermia in rats via activation of dopamine D1 receptors. Neurosci Lett. 1997 Oct 24;236(1):57-9. PubMed PMID: 9404951. 9: Salmi P, Ahlenius S. Further evidence for clozapine as a dopamine D1 receptor agonist. Eur J Pharmacol. 1996 Jun 20;307(1):27-31. PubMed PMID: 8831100. 10: Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Grønvald F, Swahn CG, Hall H, Sedvall G. [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol. 1993 Nov;20(8):945-53. PubMed PMID: 8298574. 11: Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl). 1993;113(2):149-56. PubMed PMID: 7855175. 12: Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):45-52. PubMed PMID: 1397049. 13: Nielsen EB, Andersen PH. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):35-44. PubMed PMID: 1397048.